Clinical Study Of Short-term Continuously Subcutaneous Insulin Infusion Combined With Rosiglitazone In Intensively Treating Newly Diagnosed Type 2 Diabetes Mellitus

The purpose of this study was to evaluate the effect of short-term continuously subcutaneous insulin infusion (CSII) combined with Rosiglitazone on newly diagnosed type 2 diabetic patients.Methods:60 newly diagnosed type 2 diabetic patients were randomized to the group of CSII combined with Rosiglitazone as treatment group or CSII alone as control group for 2 weeks.The levels of blood glucose ,HbA1c,the therapeutic duration, the amount of insulin, the mean areas under the curve (AUC) of insulin and C-peptide, Homa IR, Homa B and ISI between the two groups were compared at 2 weeks with the baseline. 2 weeks later,the patients in treatment group continued with Rosiglitazone. All the patients complied with diet and exercises, who were followed up for their glycemic control conditions for at least 6 months.Results:The levels of fasting plasma glucose, 2 hours postprandial glucose , HbA1c in both groups were significantly decreased at 2 weeks. The mean AUCs of insulin and C-peptide, Homa B and ISI were...